Edition:
India

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

4.00USD
20 Apr 2018
Change (% chg)

$-0.20 (-4.76%)
Prev Close
$4.20
Open
$4.25
Day's High
$4.25
Day's Low
$3.97
Volume
31,057
Avg. Vol
56,847
52-wk High
$5.40
52-wk Low
$2.25

Select another date:

Tue, Apr 17 2018

BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018

* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Compugen Announces Exclusive License Agreement With Medimmune

* CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES Source text (https://bit.ly/2GsywkV) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Compugen, AstraZeneca unit in cancer drug development deal

JERUSALEM, April 2 Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million.

BRIEF-Compugen Reports Q4 Loss Per Share Of $0.18

* COMPUGEN - AS OF DEC 31, 2017, CASH, CASH RELATED ACCOUNTS, SHORT-TERM AND LONG-TERM BANK DEPOSITS TOTALED $30.4 MILLION, COMPARED WITH $61.5 MILLION LAST YEAR Source text for Eikon: Further company coverage:

BRIEF-COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19

* ‍AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016​ Source text for Eikon: Further company coverage:

BRIEF-Compugen to initiate manufacturing of COM902

* Compugen Ltd - ‍advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019​

Select another date: